Related Experiment Video
Updated: Aug 24, 2025
Experimental Metastasis Assay
Published on: August 24, 2010
SSX addiction in melanoma propagates tumor growth and metastasis
Sofie Traynor1, Malene Laage Ebstrup1, Odd Lilleng Gammelgaard1
1Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Abstract:
Cancer/testis antigens are receiving attention as targets for cancer therapy due to their germ- and cancer cell-restricted expression. However, many of these antigens are inconsistently expressed among cancer types and individual tumors. Here, we show that members of the SSX cancer/testis antigen family comprise attractive targets in the majority of melanoma patients, as SSX is expressed in more than 90% of primary melanomas and metastases and plays a critical role in metastatic progression. Accordingly, SSX silencing in melanoma mouse xenograft models reduced tumor growth and completely abolished the formation of metastatic lesions in lungs and livers. Mechanistically, we demonstrate that silencing SSX in melanoma cells induces cell cycle S-phase stalling, leading to proliferative arrest and enhanced apoptosis, which elucidates the inhibitory effect of SSX loss on tumor growth and colonization capacity. Silencing SSX further compromised the capacity of melanoma cells to migrate and invade, influencing these cells' capability to spread and colonize. Taken together, these studies highlight SSX proteins as pivotal targets in melanoma with implications for blocking metastatic progression.
Insights
SSX cancer antigens are key targets for melanoma therapy, found in over 90% of tumors. Silencing SSX inhibits melanoma growth and metastasis by halting cell cycle progression.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Cancer/testis antigens are investigated as cancer therapy targets due to restricted expression.
- Inconsistent expression of many cancer/testis antigens limits their therapeutic utility.
- The SSX family of cancer/testis antigens shows promise as melanoma therapeutic targets.
Purpose of the Study:
- To investigate the expression and role of SSX cancer/testis antigens in melanoma.
- To evaluate SSX as a therapeutic target for melanoma, particularly concerning metastasis.
Main Methods:
- Analysis of SSX expression in melanoma patient samples (primary and metastatic).
- Utilized melanoma mouse xenograft models to assess the impact of SSX silencing on tumor growth and metastasis.
- Investigated the molecular mechanisms underlying SSX's role in melanoma cell proliferation, apoptosis, migration, and invasion.
Main Results:
- SSX expression was detected in over 90% of primary melanomas and metastases.
- SSX silencing significantly reduced tumor growth in xenograft models.
- SSX silencing completely abolished the formation of lung and liver metastases.
- Mechanistically, SSX silencing led to S-phase cell cycle arrest, increased apoptosis, and reduced cell migration and invasion.
Conclusions:
- SSX proteins are highly expressed in melanoma and play a critical role in metastatic progression.
- Targeting SSX presents a promising therapeutic strategy for blocking melanoma growth and metastasis.
- SSX is a pivotal target for developing novel melanoma therapies aimed at preventing disease spread.
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:17The Tumor Microenvironment